BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3101070)

  • 21. New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse.
    Giuliani FC; Kaplan NO
    Cancer Res; 1980 Dec; 40(12):4682-7. PubMed ID: 7438099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity and toxicity in animals of RR-150 (7-cysteaminomitosane), a new mitomycin derivative.
    Bradner WT; Rose WC; Schurig JE; Schlein A; Huftalen JB
    Cancer Res; 1984 Dec; 44(12 Pt 1):5619-23. PubMed ID: 6437670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro antitumor activity of 7-N-(p-hydroxyphenyl)-mitomycin C (KW-2083) against cultured bronchogenic carcinoma cells (PC-7)].
    Shimizu E; Saijo N; Shibuya M; Takizawa T; Fujioka Y; Hoshi A
    Gan No Rinsho; 1983 Sep; 29(11):1303-5. PubMed ID: 6415316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular comparisons of acquired and native mitomycin C resistance in human colon carcinoma cells.
    Chakrabarty S; Brattain MG
    Cancer Lett; 1987 Nov; 37(3):267-76. PubMed ID: 3119191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of bis-carbamoyloxymethyl derivatives of pyrroles and pyrrolizines against human tumor xenografts in nude mice.
    Anderson WK
    Cancer Res; 1982 Jun; 42(6):2168-70. PubMed ID: 6280852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compositional stability of artificial heterogeneous tumors in vivo: use of mitomycin C as a cytotoxic probe.
    Leith JT; Faulkner LE; Bliven SF; Michelson S
    Cancer Res; 1988 May; 48(10):2669-73. PubMed ID: 3129182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells.
    Lee JH; Naito M; Tsuruo T
    Cancer Res; 1994 May; 54(9):2398-403. PubMed ID: 8162587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.
    Keyes SR; Fracasso PM; Heimbrook DC; Rockwell S; Sligar SG; Sartorelli AC
    Cancer Res; 1984 Dec; 44(12 Pt 1):5638-43. PubMed ID: 6437671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caffeine sensitive recovery of mitomycin C treated mouse P-388 cells.
    Orstavik J
    Acta Pathol Microbiol Scand B Microbiol Immunol; 1972; 80(6):900-4. PubMed ID: 4509396
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug responses of S-180 tumours in syngeneic and xenogeneic hosts.
    Chowdhury T; Lahiri T
    Indian J Exp Biol; 1986 Feb; 24(2):81-4. PubMed ID: 3089929
    [No Abstract]   [Full Text] [Related]  

  • 31. Influence of hyperbaric oxygenation on the anticancer effect of alkylating agents (endoxan and mitomycin-C).
    Miyamoto Y
    Kumamoto Med J; 1968 Sep; 21(3):108-13. PubMed ID: 5708370
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effect of certain chemicals on DNA synthesis and distribution in human transplantable gastrointestinal tumors].
    Revazova ES; Petrova AS; Iudicheva TV; Zubrikhina GN
    Biull Eksp Biol Med; 1981 Feb; 91(2):207-8. PubMed ID: 7225560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of mitomycin C on specific gene transcript levels in cultured mammalian cells.
    Aller P
    Rev Esp Fisiol; 1987 Dec; 43(4):415-20. PubMed ID: 3129765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring the effect of an anti-cancer drug on RPMI 4788 cells by a membrane potential probe, dis-C3-(5).
    Iwagaki H; Fuchimoto S; Shiiki S; Miyake M; Orita K
    J Med; 1989; 20(2):135-41. PubMed ID: 2504864
    [No Abstract]   [Full Text] [Related]  

  • 35. Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative.
    Bradner WT; Rose WC; Schurig JE; Florczyk AP; Huftalen JB; Catino JJ
    Cancer Res; 1985 Dec; 45(12 Pt 1):6475-81. PubMed ID: 3933826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial: mitomycin c and methotrexate combination therapy for advanced colorectal carcinoma.
    Budman DR; Schulman P; Vinciguerra V; Degnan T
    Cancer Treat Rep; 1981; 65(5-6):535. PubMed ID: 7237477
    [No Abstract]   [Full Text] [Related]  

  • 37. [A model for the sensitivity determination of anticancer agents against human cancer using nude mice].
    Kondo T; Imaizumi M; Taguchi T; Abe O; Hattori T; Wakui A; Kitano M
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):680-6. PubMed ID: 3103538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [In vitro sensitivity test of a cultured human ovarian cancer cell line to anticancer agents].
    Fujiya S; Yasuda M; Tahira K; Nakabayashi Y; Yoshioka M; Terashima Y; Hatiya S
    Gan To Kagaku Ryoho; 1985 May; 12(5):1080-7. PubMed ID: 3922310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions of mitomycin C with mammalian DNA detected by alkaline elution.
    Dorr RT; Bowden GT; Alberts DS; Liddil JD
    Cancer Res; 1985 Aug; 45(8):3510-6. PubMed ID: 3926301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Partial characterization of a mitomycin-C resistant T cell.
    Anderson RE; Standefer JC; Troup GM; Pogue LE
    J Leukoc Biol; 1987 Jan; 41(1):33-9. PubMed ID: 3100710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.